- Citations, last 5 years
- 63
- Works, last 5 years
- 8
- h-index
- 34
- Scientists listed
- 6
- Grants since 2016
- 19
Grants received
2025–2026 · research · R44
Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through murine studies to enable further clinical advancement in non-small-cell lung cancer
Kenneth Schultz · Trex (United States) · funded by National Institutes of Health
2025–2028 · research · R44
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus
Kenneth Schultz · Trex (United States) · funded by National Institutes of Health
2025–2027 · research · R44
Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through combinatorial murine studies to enable further clinical advancement in prostate tumors
Kenneth Schultz · Trex (United States) · funded by National Institutes of Health
2024–2026 · research · R44
Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through IND enabling studies and translational mouse models for acute disseminated encephalomyelitis (ADEM)
Kenneth Schultz · Trex (United States) · funded by National Institutes of Health
2024–2026 · research · R44
Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through IND enabling studies and translational mouse models for acute disseminated encephalomyelitis (ADEM)
Kenneth Schultz · Trex (United States) · funded by National Institutes of Health
2023–2024 · research · R41
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Crohn's disease
Kenneth Schultz · Trex (United States) · funded by National Institutes of Health
2023–2025 · research · R41
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus
Kenneth Schultz · Trex (United States) · funded by National Institutes of Health
2023–2025 · research · R41
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Acute Disseminated Encephalomyelitis (ADEM)
Kenneth Schultz · Trex (United States) · funded by National Institutes of Health
2023–2025 · research · R41
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Acute Disseminated Encephalomyelitis (ADEM)
Kenneth Schultz · Trex (United States) · funded by National Institutes of Health
2023–2025 · research · R44
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleotide Salvage Pathway to Treat Underserved Tumor Types
Kenneth Schultz · Trex (United States) · funded by National Institutes of Health
2023–2025 · research · R44
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleotide Salvage Pathway to Treat Underserved Tumor Types
Kenneth Schultz · Trex (United States) · funded by National Institutes of Health
2023–2025 · research · R41
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus
Kenneth Schultz · Trex (United States) · funded by National Institutes of Health
2023–2027 · research · R42
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Crohn's disease
Kenneth Schultz · Trex (United States) · funded by National Institutes of Health
2022–2024 · research · R42
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Optic Neuritis
Kenneth Schultz · Trex (United States) · funded by National Institutes of Health
2022–2026 · research · R42
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Optic Neuritis
Kenneth Schultz · Trex (United States) · funded by National Institutes of Health
2022–2026 · research · R42
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Optic Neuritis
Kenneth Schultz · Trex (United States) · funded by National Institutes of Health
2021–2025 · research · R42
Optimizing Radiosynthetic Yield of [18F]FTT For Wide-Spread Distribution
Hsiaoju Sharon Lee · Trex (United States) · funded by National Institutes of Health
2021–2025 · research · R42
Optimizing Radiosynthetic Yield of [18F]FTT For Wide-Spread Distribution
Hsiaoju Sharon Lee · Trex (United States) · funded by National Institutes of Health
2021–2022 · research · R41
Optimizing Radiosynthetic Yield of [18F]FTT For Wide-Spread Distribution
Hsiaoju Sharon Lee · Trex (United States) · funded by National Institutes of Health